EUVIMEDObjevte EUVIMED
Open access · CC BY-NC 4.0

Utilization of antiobesity medications within the Military Health System

Taylor Neuman iD, Richele Corrado, Amanda Banaag, Tracey Perez Koehlmoos

Obesity · 2024

DOI: 10.1002/oby.24097 ↗

At a glance

Journal article in Obesity, 2024. Written by Taylor Neuman and 3 co-authors. Institution: Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA. Major MEDLINE topics: Anti-Obesity Agents, Obesity. Cited 1 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Department of Defense, Defense Health Agency, U.S. Department of Defense.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

The prevalence of overweight and obesity among beneficiaries of the Military Health System (MHS) is 41.6% and 30.5%, respectively. This incurs significant medical, fiscal, and military readiness costs. It is not currently known how the utilization of antiobesity medications (AOMs) within the MHS compares with that in the Veterans Health Administration or the private sector. Our aim was to assess the utilization of AOMs within the MHS.

Methods

A cross‐sectional study was conducted using data gathered from the MHS Data Repository and the inclusion of all adult TRICARE Prime and Plus beneficiaries ages 18 to 64 years who were prescribed at least one TRICARE‐approved AOM during the years 2018 to 2022.

Results

The total study population included 4,414,127 beneficiaries, of whom 1,871,780 were active‐duty service members. The utilization of AOMs among the eligible population was 0.56% (0.44% among active‐duty personnel). Liraglutide was the most‐prescribed AOM (36% of the total). Female sex, age greater than or equal to 30 but less than 60 years, and enlisted or warrant officer rank were all associated with statistically significant higher odds of receiving AOMs.

Conclusions

Comparable with the US private sector, the MHS significantly underutilizes AOMs, including among active‐duty service members, despite coverage of AOMs since 2018.

Subjects

MeSH terms (MEDLINE)

Anti-Obesity AgentsObesityHumansFemaleMaleAdultMiddle AgedCross-Sectional StudiesUnited StatesYoung AdultAdolescentMilitary PersonnelLiraglutideMilitary HealthOverweightPrivate SectorUnited States Department of Veterans AffairsPrevalence

Substances

Anti-Obesity AgentsLiraglutide

Authors and institutions

  • Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
  • Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Center for Health Services Research, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.

ORCID profiles: Taylor Neuman

Funding

  • Department of Defense, Defense Health Agency
  • U.S. Department of Defense

Cite

APA

Neuman, T., Corrado, R., Banaag, A., & Koehlmoos, T. P. (2024). Utilization of antiobesity medications within the Military Health System. Obesity. https://doi.org/10.1002/oby.24097

Vancouver

Neuman T, Corrado R, Banaag A, Koehlmoos TP. Utilization of antiobesity medications within the Military Health System. Obesity. 2024. doi:10.1002/oby.24097

BibTeX
@article{Neuman2024,
  author = {Neuman, Taylor and Corrado, Richele and Banaag, Amanda and Koehlmoos, Tracey Perez},
  title = {Utilization of antiobesity medications within the Military Health System},
  journal = {Obesity},
  year = {2024},
  doi = {10.1002/oby.24097}
}
Start for free →